BTG earns significant revenues from product sales and royalties from marketed products, some of which are shown in the table below.
|
Product |
Partner |
Indication/Description |
|
BeneFIX® |
Wyeth |
The first recombinant Factor IX therapy approved for the treatment of haemophilia B |
| CroFab™ |
Nycomed in the US until 2010; Swedish Orphan International AB for Nordic countries; BTG for other EU countries and the rest of the world |
An antidote used to treat mild or moderate envenomation from Crotalid snakes, which includes rattlesnakes, found in the US
Click here for more information |
|
Two-Part Hip Cup |
All major orthopaedic companies, including Zimmer Holdings Inc, Stryker Corporation, Smith & Nephew Inc and Biomet Inc |
Prosthetic hip joint replacement which allows an improved range of motion that helps to avoid dislocation |
|
Campath® |
Genzyme Corporation |
A humanised anti-lymphocyte antibody approved for treatment of B-cell chronic lymphocytic leukaemia
Click here for more information |
| DigiFab™ |
Nycomed for the US until 2010; Beacon Pharmaceuticals in the EU (excluding Nordic countries); local partners and BTG for the rest of the world |
An antidote to treat patients with life-threatening digoxin (digitalis) toxicity or overdose
Click here for more information |
|
Three-Part Knee |
Biomet Merck Ltd and Corin Ltd |
Unicompartmental knee joint replacement designed to give more freedom of movement similar to that of a natural knee |
Although not an approved or marketed drug, ViperaTAb™, an antidote for the treatment of snakebites from the European common adder (Vipera berus) is also available in Europe on a named patient basis. Click here for more information.